DominiciMLe BlancKMuellerI, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy2006; 8(4): 315–317.
2.
De OliveiraGLde LimaKWColombiniAM, et al. Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. Cell Transplant2015; 24(2): 151–165.
3.
PetrouPKassisILevinN, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain2020; 143: 3574–3588.
4.
PetrouPKassisIGinzbergA, et al. Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Translational Medicine2022; 11: 55–58.
5.
PetrouPKassisIGinzbergA, et al. Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis. Front Neurol2021; 12: 639315.
6.
UccelliALaroniAAliR, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): A phase 2, randomised, double-blind crossover trial. Lancet Neurol2021; 20(11): 917–929.
7.
PluchinoSSmithJAPeruzzotti-JamettiL. Promises and limitations of neural stem cell therapies for progressive multiple sclerosis. Trends Mol Med2020; 26(10): 898–912.
8.
PinhoAGCibraoJRSilvaNA, et al. Cell secretome: Basic insights and therapeutic opportunities for CNS disorders. Pharmaceuticals2020; 13: 31.
9.
PittengerMFDischerDEPeaultBM, et al. Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen Med2019; 4: 22.
10.
MasterZRobertsonKFrederickD, et al. Stem cell tourism and public education: The missing elements. Cell Stem Cell2014; 15: 267–270.
